Zobrazeno 1 - 10
of 277
pro vyhledávání: '"Andrew Lees"'
Autor:
Ella Burchill, Cameron James Watson, Jack B. Fanshawe, James Brunton Badenoch, Emma Rengasamy, Dory Anthony Ghanem, Constantine Holle, Isabella Conti, Mohammed Ahmed Sadeq, Aman Saini, Abdelilah Lahmar, Ben Cross, Gareth McGuigan, Amar Nandrha, Edward J. Kane, Julia Wozniak, Reem Mohamed Farouk Ghorab, Jia Song, Andrew Sommerlad, Andrew Lees, Michael S. Zandi, Anthony S. David, Glyn Lewis, Ben Carter, Jonathan P. Rogers
Publikováno v:
The Lancet Regional Health. Europe, Vol 39, Iss , Pp 100870- (2024)
Summary: Background: The burden of psychiatric symptoms in Parkinson's disease includes depression, anxiety, apathy, psychosis, and impulse control disorders. However, the relationship between psychiatric comorbidities and subsequent prognosis and ne
Externí odkaz:
https://doaj.org/article/4413b43557224f86bc37a9d5c3641e4d
Autor:
José-Francisco Rocha, Georg Ebersbach, Andrew Lees, Eduardo Tolosa, Joaquim J. Ferreira, Werner Poewe, Olivier Rascol, Fabrizio Stocchi, Angelo Antonini, Diogo Magalhães, Helena Gama, Patrício Soares-da-Silva
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
IntroductionPost-hoc analyses of the BIPARK-I and II trials previously demonstrated that opicapone (OPC) 50 mg was efficacious over the whole trajectory of motor fluctuation evolution in patients with Parkinson's disease (PD) and end-of-dose motor fl
Externí odkaz:
https://doaj.org/article/e75ee9d511ff4eaea3a6ca96d9d9a0ef
Autor:
Heinz Reichmann, Andrew Lees, José-Francisco Rocha, Diogo Magalhães, Patrício Soares-da-Silva, the OPTIPARK investigators
Publikováno v:
Translational Neurodegeneration, Vol 9, Iss 1, Pp 1-9 (2020)
Abstract Background The efficacy and safety of opicapone, a once-daily catechol-O-methyltransferase inhibitor, have been established in two large randomized, placebo-controlled, multinational pivotal trials. Still, clinical evidence from routine prac
Externí odkaz:
https://doaj.org/article/f1d7f45738a946a49d3e6518b23cf907
Autor:
Tatiana Orme, Dena Hernandez, Owen A. Ross, Celia Kun-Rodrigues, Lee Darwent, Claire E. Shepherd, Laura Parkkinen, Olaf Ansorge, Lorraine Clark, Lawrence S. Honig, Karen Marder, Afina Lemstra, Ekaterina Rogaeva, Peter St. George-Hyslop, Elisabet Londos, Henrik Zetterberg, Kevin Morgan, Claire Troakes, Safa Al-Sarraj, Tammaryn Lashley, Janice Holton, Yaroslau Compta, Vivianna Van Deerlin, John Q. Trojanowski, Geidy E. Serrano, Thomas G. Beach, Suzanne Lesage, Douglas Galasko, Eliezer Masliah, Isabel Santana, Pau Pastor, Pentti J. Tienari, Liisa Myllykangas, Minna Oinas, Tamas Revesz, Andrew Lees, Brad F. Boeve, Ronald C. Petersen, Tanis J. Ferman, Valentina Escott-Price, Neill Graff-Radford, Nigel J. Cairns, John C. Morris, Stuart Pickering-Brown, David Mann, Glenda Halliday, David J. Stone, Dennis W. Dickson, John Hardy, Andrew Singleton, Rita Guerreiro, Jose Bras
Publikováno v:
Acta Neuropathologica Communications, Vol 8, Iss 1, Pp 1-11 (2020)
Abstract Dementia with Lewy bodies (DLB) is a clinically heterogeneous disorder with a substantial burden on healthcare. Despite this, the genetic basis of the disorder is not well defined and its boundaries with other neurodegenerative diseases are
Externí odkaz:
https://doaj.org/article/eb7da7eb422d4a428e7652ae48f842e3
Autor:
José-Francisco Rocha, Georg Ebersbach, Andrew Lees, Eduardo Tolosa, Joaquim J. Ferreira, Werner Poewe, Olivier Rascol, Fabrizio Stocchi, Angelo Antonini, Diogo Magalhães, Helena Gama, Patrício Soares-da-Silva
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Introduction: Opicapone (OPC) was efficacious in reducing OFF-time in two pivotal trials in patients with Parkinson's disease (PD) and end-of-dose motor fluctuations (BIPARK-I and -II). Post-hoc analyses of these trials evaluated the efficacy of OPC
Externí odkaz:
https://doaj.org/article/202fb31b049d40719834b2f73826e988
Autor:
Heinz Reichmann, Andrew Lees, José-Francisco Rocha, Diogo Magalhães, Patrício Soares-da-Silva, the OPTIPARK investigators
Publikováno v:
Translational Neurodegeneration, Vol 9, Iss 1, Pp 1-3 (2020)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://doaj.org/article/099eb9674bc94871a1f76b67a87da240
Autor:
Rita Guerreiro, Valentina Escott-Price, Dena G. Hernandez, Celia Kun-Rodrigues, Owen A. Ross, Tatiana Orme, Joao Luis Neto, Susana Carmona, Nadia Dehghani, John D. Eicher, Claire Shepherd, Laura Parkkinen, Lee Darwent, Michael G. Heckman, Sonja W. Scholz, Juan C. Troncoso, Olga Pletnikova, Ted Dawson, Liana Rosenthal, Olaf Ansorge, Jordi Clarimon, Alberto Lleo, Estrella Morenas-Rodriguez, Lorraine Clark, Lawrence S. Honig, Karen Marder, Afina Lemstra, Ekaterina Rogaeva, Peter St. George-Hyslop, Elisabet Londos, Henrik Zetterberg, Imelda Barber, Anne Braae, Kristelle Brown, Kevin Morgan, Claire Troakes, Safa Al-Sarraj, Tammaryn Lashley, Janice Holton, Yaroslau Compta, Vivianna Van Deerlin, Geidy E. Serrano, Thomas G. Beach, Suzanne Lesage, Douglas Galasko, Eliezer Masliah, Isabel Santana, Pau Pastor, Monica Diez-Fairen, Miquel Aguilar, Pentti J. Tienari, Liisa Myllykangas, Minna Oinas, Tamas Revesz, Andrew Lees, Brad F. Boeve, Ronald C. Petersen, Tanis J. Ferman, Neill Graff-Radford, Nigel J. Cairns, John C. Morris, Stuart Pickering-Brown, David Mann, Glenda M. Halliday, John Hardy, John Q. Trojanowski, Dennis W. Dickson, Andrew Singleton, David J. Stone, Jose Bras
Publikováno v:
Neurobiology of Disease, Vol 127, Iss , Pp 492-501 (2019)
Recent large-scale genetic studies have allowed for the first glimpse of the effects of common genetic variability in dementia with Lewy bodies (DLB), identifying risk variants with appreciable effect sizes. However, it is currently well established
Externí odkaz:
https://doaj.org/article/8a8a606f7f4c49d690647ef64ba97f82
Autor:
Matthew Butler, Mathieu Seynaeve, Timothy R. Nicholson, Susannah Pick, Richard A. Kanaan, Andrew Lees, Allan H. Young, James Rucker
Publikováno v:
Therapeutic Advances in Psychopharmacology, Vol 10 (2020)
Functional neurological disorder (FND), formerly known as conversion disorder, causes a high burden of disability and distress, and is amongst the most commonly encountered conditions in neurology clinics and neuropsychiatric services, yet the therap
Externí odkaz:
https://doaj.org/article/6ccd384403aa4f0db74c05ef8c2eaf1b
Publikováno v:
Vaccines, Vol 8, Iss 4, p 777 (2020)
CDAP (1-cyano-4-dimethylaminopyridine tetrafluoroborate) is employed in the synthesis of conjugate vaccines as a cyanylating reagent. In the published method, which used pH 9 activation at 20 °C (Vaccine, 14:190, 1996), the rapid reaction made the p
Externí odkaz:
https://doaj.org/article/55a4ee0b28884b3eafde4123b46ec2c4
Autor:
Nicolas Hegerle, Myeongjin Choi, James Sinclair, Mohammed N Amin, Morgane Ollivault-Shiflett, Brittany Curtis, Rachel S Laufer, Surekha Shridhar, Jerod Brammer, Franklin R Toapanta, Ian Alan Holder, Marcela F Pasetti, Andrew Lees, Sharon M Tennant, Alan S Cross, Raphael Simon
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0203143 (2018)
Klebsiella pneumoniae (KP) and Pseudomonas aeruginosa (PA) are important human pathogens that are associated with a range of infection types, including wound and disseminated infections. Treatment has been complicated by rising rates of antimicrobial
Externí odkaz:
https://doaj.org/article/77d21b49b7734efc8c1eea23ff9e702e